TNON vs XWEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.
XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.
Compare Another Pair
Related Comparisons
TNON vs XWEL: Head-to-Head Comparison
This page compares Tenon Medical, Inc. (TNON) and XWELL, Inc. (XWEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.